Key Highlights

  • Third quarter Revenue was USD 275.36 million against a USD 255.36 million estimate and USD 216.83 million a year earlier.
  • EPS was USD 0.05 against an estimate of USD 0.03, compared with USD 0.08 in the prior-year quarter.
  • Clinical cases reached 61,500 against 50,800, and molecular profiling services revenue was USD 262.71 million.
  • Cash, restricted cash and marketable securities were USD 769.2 million, with USD 400.0 million of term Loan principal outstanding.

Caris Life Sciences (NASDAQ:CAI) frames its direction around a widening test menu, and the third quarter shows where that stands. The company launched Caris ChromoSeq, Caris Detect and Caris MI Clarity in the second quarter of 2026, and management cited higher testing volumes and menu expansion as contributors to growth in 2026 and beyond. Revenue was USD 275.36 million against an estimate of USD 255.36 million, and EPS was USD 0.05 against an estimate of USD 0.03.

Priorities and Financing Management Named

Management listed the factors it watches: market acceptance of its solutions, biopharma partnerships, new product development, payer coverage and reimbursement, and scaling lab infrastructure. It said realizing the potential of Caris Assure and Caris Detect across the cancer treatment continuum is a key part of its strategy, and that further validation studies are needed for early detection, MCED, MRD tracking and treatment monitoring.

On April 1, the company entered a financing agreement with Blackstone and Blue Owl funds and drew USD 400.0 million, maturing April 1, 2031, interest-only quarterly. The agreement also offers a committed delayed draw Facility of up to USD 300.0 million through August 2027 for permitted acquisitions, none of which was drawn at September 30, and an uncommitted incremental facility of up to USD 500.0 million. The rate in effect was 8.7%, and the company said it was in compliance with all covenants, including a USD 50.0 million minimum qualified cash requirement.

The Quarter in Detail

Total revenue of USD 275.36 million increased 27.0% from USD 216.83 million. Net Income was USD 15.25 million against USD 24.33 million, and income from operations was USD 19.32 million against USD 32.64 million. Diluted EPS was USD 0.05 against USD 0.08.

Operating costs moved with the larger business. Selling and Marketing expense was USD 59.85 million against USD 41.27 million, reflecting sales team expansion. General and administrative expense was USD 69.28 million against USD 51.97 million, and Research and Development expense was USD 33.84 million against USD 21.62 million. Interest expense was USD 9.25 million against USD 13.51 million, which management attributed to the Debt refinancing that lowered the rate.

Molecular Profiling and Pharma Services

Molecular profiling services revenue was USD 262.71 million against USD 207.59 million, up 26.6%. The company tied the gain to higher clinical case Volume and higher reimbursement, including improved average selling prices from enhanced contracting and collection capabilities. Clinical cases were approximately 61,500 against 50,800. Medicare-covered patients accounted for approximately 36.9% of molecular profiling revenue, against 39.4%.

Pharma research and development services revenue was USD 12.65 million against USD 9.25 million, which the company attributed to the timing of service delivery. For the nine months, total revenue was USD 755.24 million against USD 519.15 million.

Reference Points for Investors

Revenue of USD 275.36 million sits alongside net income of USD 15.25 million, nine-month Operating Cash Flow of USD 39.1 million and cash, cash equivalents, restricted cash and marketable securities of USD 769.2 million.

Nine-month investing outflows of USD 150.0 million included USD 102.0 million of marketable securities purchases and USD 49.9 million of property and equipment. Financing outflows of USD 21.8 million included USD 406.3 million repaid on the 2023 term loan and USD 31.4 million of share repurchases, against USD 393.5 million of net proceeds from the new loan.